GlassScriptPhysician profile
Alexis Voke
NPI 1083252126
$2,860.46
in general payments reported to CMS, 2019-2025
24 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $259 · 2023: $755 · 2024: $677 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $340.42 | 2022-2025 | Caplyta |
| Abbvie INC. | $331.82 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.86 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $237.78 | 2023-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $232.48 | 2024-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $179.82 | 2023-2025 | Trelegy Ellipta |
| Viiv Healthcare Company | $167.81 | 2025 | Apretude |
| Exact Sciences Corporation | $138.61 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $125.92 | 2023-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.66 | 2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $117.18 | 2022 | |
| Antares Pharma, INC. | $112.72 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Esperion Therapeutics, INC. | $104.89 | 2023-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $80.76 | 2024 | |
| Sumitomo Pharma America, INC. | $66.85 | 2025 | Gemtesa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.08 | 2025 | |
| Axsome Therapeutics, INC. | $37.71 | 2023-2024 | Auvelity, Sunosi |
| Novo Nordisk INC | $37.49 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lundbeck LLC | $30.71 | 2024 | Rexulti |
| Acella Pharmaceuticals, LLC | $29.51 | 2024-2025 | NP Thyroid 60 |
| Halozyme INC | $25.35 | 2023 | |
| Tolmar, INC. | $17.43 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $17.00 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $15.60 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Voke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.